Title
A review on mTOR inhibitor use and outcomes of COVID-19 among patients with kidney transplantation
Authors
Sawai Singh Rathore1#,*, Vanessa Vidaurre Corrales2# , Ashwin Hassan Gopala3, Hamam Aneis4, Ibrahim Marouf Yasin Al Shyyab5, Mutaz AlBeetar5, Samah Mohamed Kannas5, Omar Jihad Saleh Almistarihi6 & Mohamed Hamed Daoud7
Affiliation
1Department of Internal Medicine, Dr. Sampurnanand Medical College, Jodhpur, Rajasthan, India; 2Department of Internal Medicine, Universidad Privada del Valle, Cochabamba, Bolivia; 3Department of Internal Medicine, Jinzhou Medical College, Jinzhou, China; 4Department of Internal Medicine, UPMC, Mckeesport, Pennsylvania; 5Department of Internal Medicine, University of Sharjah, Sharjah, UAE; 6Department of Internal Medicine, Fakeeh University Hospital, Dubai, UAE; 7Department of Internal Medicine, Bogomolets National Medical University, Kyiv, Ukraine; *Corresponding author, #These authors have contributed equally to this work and share first authorship
Sawai Singh Rathore - E-mail: Sawais.rathore77@gmail.com
Vanessa Vidaurre Corrales - E-mail: vanessavidaurre23@hotmail.com
Ashwin Hassan Gopala - E-mail: iashwinhg19@gmail.com
Hamam Aneis - E-mail: Homam-1@hotmail.com
Ibrahim Marouf Yasin Al Shyyab - E-mail: ibrahimshayyab6000@yahoo.com
Mutaz AlBeetar - E-mail: Motaz.albitar@hotmail.com
Samah Mohamed Kannas - E-mail: s.kannas@outlook.com
Omar Jihah Saleh Almistarihi - E-mail: omarmist@hotmail.com
Mohamed Hamed Daoud - E-mail: Daoudmohd99@gmail.com
Article Type
Review
Date
Received June 30, 2025; Revised June 30, 2025; Accepted June 30, 2025, Published June 30, 2025
Abstract
Kidney transplant recipients are at increased risk of severe COVID-19 due to immunosuppression and the impact of mTOR inhibitors on outcomes remains unclear. Hence, we evaluated 24 observational studies with 5,882 kidney transplant patients to assess the association of mTOR inhibitors with COVID-19 severity and mortality. Random-effects models showed that mTOR inhibitors were significantly associated with reduced mortality (OR=0.63, 95% CI 0.48–0.83, P=0.001) but not with COVID-19 severity (OR=0.70, 95% CI 0.41–1.20, P=0.865). Thus, mTOR inhibitors may provide a survival benefit in kidney transplant patients with COVID-19, highlighting the need for further research.
Keywords
Kidney transplant, COVID-19, SARS-CoV-2, renal transplant; hospitalization, ICU admission, mortality, mTOR inhibitors, irolimus, everolimus, temsirolimus
Citation
Rathore et al. Bioinformation 21(6): 1447-1453 (2025)
Edited by
P Kangueane
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
